CADL Sale Disclosure
Tak Paul Peter · SEC Form 4 · Filed Sep 11, 2026
Sale
Calculated transaction value
$620.89K
Tak Paul Peter Chief Executive Officer
CADL
Candel Therapeutics
CADL
Transaction date
Sep 11, 2026
Public filing date
Sep 11, 2026
Filing lag
Filed same day
CADL daily price context
Close on/before transaction
$10.4
Sep 11, 2026
Close before public filing
$11.33
Sep 10, 2026
Return since public filing
-8.21%
Through Sep 11, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 59,379 shares @ $10.46
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001873905-26-000002
Filing cohort
Transactions in this filing
Showing 4 of 4
Trades
4
Issuers
1
Estimated value
$3.35M
Buys / sales
0 / 2
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Candel Therapeutics, Inc. CADL Current | Sale | Sep 11, 2026 | $620.89K |
| Candel Therapeutics, Inc. CADL | Exercise | Sep 10, 2026 | $193.75K |
| Candel Therapeutics, Inc. CADL | Sale | Sep 10, 2026 | $2.54M |
| Candel Therapeutics, Inc. CADL | Exercise | Sep 10, 2026 | $0 |